GoalVest Advisory LLC Sells 6,171 Shares of AbbVie Inc. $ABBV

Key Points

• GoalVest Advisory LLC cut its AbbVie stake by 48.4% in the second quarter, selling 6,171 shares and retaining 6,577 shares worth approximately $1.66 million. Institutional investors and hedge funds collectively own 70.23% of ABBV.
• AbbVie exceeded quarterly expectations with adjusted EPS of $3.65 and revenue of $16.99 billion, up 10.2% year over year. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• Analyst sentiment remains positive, with AbbVie receiving a “Moderate Buy” consensus rating and an average price target of $275.70, above its reported opening price of $245.82. The company also declared a quarterly dividend of $1.73 per share, representing a 2.8% yield.

GoalVest Advisory LLC decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 48.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,577 shares of the company's stock after selling 6,171 shares during the period. GoalVest Advisory LLC's holdings in AbbVie were worth $1,655,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Willner & Heller LLC raised its holdings in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after buying an additional 43 shares in the last quarter. Bank of Jackson Hole Trust lifted its position in shares of AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock worth $1,648,000 after buying an additional 44 shares during the period. Eclectic Associates Inc. ADV boosted its stake in AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company's stock valued at $1,337,000 after buying an additional 45 shares in the last quarter. Imprint Wealth LLC boosted its stake in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after buying an additional 45 shares in the last quarter. Finally, Dogwood Wealth Management LLC grew its position in AbbVie by 10.8% in the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company's stock valued at $108,000 after acquiring an additional 46 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of ABBV opened at $245.82 on Friday. The stock has a fifty day moving average price of $241.96 and a two-hundred day moving average price of $224.96. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company has a market cap of $434.31 billion, a price-to-earnings ratio of 69.44, a PEG ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business's revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie's dividend payout ratio is 195.48%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Royal Bank Of Canada increased their price objective on AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, July 10th. Weiss Ratings upgraded shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday. Morgan Stanley reaffirmed an "overweight" rating and issued a $296.00 target price on shares of AbbVie in a report on Monday, August 3rd. Barclays increased their target price on shares of AbbVie from $275.00 to $300.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Finally, DZ Bank upgraded shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and an average target price of $275.70.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source